Citations

Showing 10 of 108104 citations.

Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung disease support a direct role for IL-17A/IL-17RA in human fibrotic interstitial lung disease
Zhang, Jie , Wang, Dan , Wang, Shaohua , Roden, Anja C. , Li, Xiujuan , Prakash, Y. S. , Matteson, Eric L. , Tschumperlin, Daniel J. , Vassallo, Robert , Prakash, Y S , Vassallo, Robert , Wang, Lei , Zhao, Hao

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | January 3, 2019 | Volume: 316 | Issue: 3 | Pages: L487-L497

10.1152/ajplung.00301.2018 | PMID 30604628 Get It

Interleukin (IL)-17 is a T helper 17 cytokine implicated in the pathogenesis of many autoimmune diseases, including rheumatoid arthritis (RA). Although IL-17A has a well-established role in murine pulmonary fibrosis models, its role in the tissue remodeling and fibrosis occurring in idiopathic pulmonary fibrosis (IPF) and RA-associated interstitial lung disease (RA-ILD) is not very well defined. To address this question, we utilized complimentary studies to determine responsiveness of human normal and pathogenic lung fibroblasts to IL-17A and used lung biopsies acquired from patients with IPF and RA-ILD to determine IL-17A receptor (IL-17RA) expression. Both normal and pathogenic IPF lung fibroblasts express functional IL-17RA and respond to IL-17A stimulation with cell proliferation, generation of extracellular matrix (ECM) proteins, and induction of myofibroblast transdifferentiation. Small interfering RNA (siRNA) silencing of IL-17RA attenuated this fibroblast response to IL-17A on ECM production. These fibroblast responses to IL-17A are dependent on NF-κB-mediated signaling. In addition, inhibiting Janus activated kinase (JAK) 2 by either siRNA or a selective pharmacological inhibitor, AZD1480—but not a JAK1/JAK3 selective inhibitor, tofacitinib—also significantly reduced this IL-17A-induced fibrogenic response. Lung biopsies of RA-ILD patients demonstrate significantly higher IL-17RA expression in areas of fibroblast accumulation and fibrosis, compared with either IPF or normal lung tissue. These observations support a direct role for IL-17A in lung fibrosis that may be particularly relevant in the context of RA-ILD.
Direct thrombin inhibitor therapy in the cardiovascular patient
Chesebro, James H.

Mayo Clinic

American Journal of Health-System Pharmacy | January 3, 2019 | Volume: 60 | Issue: suppl_5 | Pages: S19-S26

10.1093/ajhp/60.suppl_5.s19 | PMID 14593979 Get It

Hall of Fame Article: Minimally Invasive and Regenerative Therapeutics (Adv. Mater. 1/2019)
Ahadian, Samad , Darabi, Mohammad Ali , Lee, Junmin , Ashammakhi, Nureddin A. , Tahchi, Mario El , Suthiwanich, Kasinan , Sheikhi, Amir , Dokmeci, Mehmet R. , Öklü, Rahmi , Khademhosseini, Ali

Mayo Clinic

Advanced Materials | January 3, 2019 | Volume: 31 | Issue: 1 | Pages: No page available

10.1002/adma.201970005 Get It

Laparoscopic Transdiaphragmatic Access to the Apex of the Left Ventricle of the Heart
Thompson, Jess L., Suri, Rakesh M. , McKellar, Stephen H. , Schaff, Hartzell V.

Mayo Clinic

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery | January 3, 2019 | Volume: 4 | Issue: 1 | Pages: 27-31

10.1177/155698450900400106 Get It

Robot-Assisted Aortic Valve Replacement Using a Novel Sutureless Bovine Pericardial Prosthesis Proof of Concept as an Alternative to Percutaneous Implantation
Suri, Rakesh M. , Burkhart, Harold M. , Schaff, Hartzell V.

Mayo Clinic

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery | January 3, 2019 | Volume: 5 | Issue: 6 | Pages: 419-423

10.1177/155698451000500607 | PMID 22437637 Get It

Objective Percutaneous aortic valve implantation within native valve calcium has progressed to clinical use despite the absence of data proving equivalence to complete surgical excision and prosthetic valve replacement. A novel self-expanding sutureless bovine pericardial prosthesis (Sorin Perceval) derived from a proven stented valve has been successfully used in humans recently through an open transaortic approach. We sought to develop a minimally invasive technique for native aortic valve excision and sutureless prosthetic aortic valve replacement using robot assistance. Methods The da Vinci S-HD system was used to open and suspend the pericardium anterior to the phrenic nerve in cadavers. A transthoracic cross-clamp was placed across the midascending aorta, following which a transverse aortotomy was made. The native aortic valve cusps were excised, and annular calcium was removed with robotic instruments. After placement of three guide sutures, the Perceval self-expanding pericardial prosthesis mounted on a flexible delivery system was inserted through a working port and lowered into the aortic annulus. Results Successful implantation of all valves was possible using a 3-cm right second intercostal space working port, along with two additional 1-cm instrument ports. A standard transverse aortotomy was sufficient for examination/debridement of the native aortic valve cusps, sizing of the annulus, and deployment of the nitinol-stented, bovine pericardial prosthesis. Delivery, seating, and stability of the device were easily confirmed above and below the aortic valve annulus using the robotic camera. Conclusions Complete excision of diseased native aortic valve cusps with robot assistance facilitates accurate and reproducible aortic valve replacement using a novel self-expanding sutureless version of a proven bovine pericardial prosthesis. This approach is comparable to the current surgical gold standard and is ready for clinical use as an alternative to percutaneous aortic valve implantation.
SynCardia Portable Freedom Driver: A Single-Center Experience with 11 Patients
Jaroszewski, Dawn E. , Schroedl, L., Staley, Linda L., Pajaro, Octavio E., Kasirajan, Vigneshwar , Arabía, Francisco A. , Shah, Nilay R., Ashfaq, Awais

Mayo Clinic

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery | January 3, 2019 | Volume: 10 | Issue: 3 | Pages: 188-194

10.1177/155698451501000308 Get It

International Expert Consensus on Sutureless and Rapid Deployment Valves in Aortic Valve Replacement Using Minimally Invasive Approaches
Moten, Simon, Quaini, Eugenio, Miceli, Antonio, Oberwalder, Peter, Rambaldini, Manfredo, Teoh, Kevin , Bhatnagar, Gopal , Bouchard, Denis , Bouchot, Olivier , Dapunt, O., Ferrarini, Matteo , Fischlein, Theodor , Millner, Russell, Noirhomme, Philippe, Pfeiffer, Steffen, Ruyra-Baliarda, Xavier, Shrestha, Malakh , Suri, Rakesh M. , Geršak, Borut , Glauber, Mattia , Solinas, Marco , Folliguet, Thierry A , Meuris, Bart , Miceli, Antonio , Borger, Michael A. , Clark, Stephen , Laufer, Günther , Mignosa, Carmelo , Troise, Giovanni

Mayo Clinic

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery | January 3, 2019 | Volume: 11 | Issue: 3 | Pages: 165-173

10.1177/155698451601100303 Get It

Concomitant Valve-In-Valve Transcatheter Aortic Valve Replacement and Left Ventricular Assist Device Implantation
Joyce, David L. , Pochettino, Alberto , Stulak, John M., Joyce, Lyle D., Murashita, Takashi

Mayo Clinic

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery | January 3, 2019 | Volume: 12 | Issue: 2 | Pages: 147-149

10.1177/155698451701200213 Get It

Message from the Mirc President
Çïçek, Sertaç

Mayo Clinic

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery | January 3, 2019 | Volume: 12 | Issue: 1_suppl | Pages: S1-S1

10.1177/155698451701201s01 Get It

Androgen Mediation—and Antiandrogens Mitigation—of the Epidermal Growth Factor Receptor (EGFR) Inhibitor–Induced Rash: Results From a Pilot Randomized Trial and Small Translational Case Series
Rowland, Kendrith M. , Atherton, Pamela J., Dakhil, Christopher, Sun, Zhifu , Tan, Angelina D., Schmidt, Lucy J., Nguyen, Phuong L., Breitkopf, Carmen Radecki , Pittelkow, Mark R. , Tindall, Donald J., Menon, Smitha, Jatoi, Aminah , Atherton, Philip J. , Tan, Angelina, Schmidt, Lucy, Tindall, Donald, Jatoi, Aminah , Sun, Zhifu , Le‐Rademacher, Jennifer , Atherton, Pamela J., Atherton, Philip J.

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | January 3, 2019 | Volume: 36 | Issue: 6 | Pages: 519-525

10.1177/1049909118819820 | PMID 30602311 Get It

Background: Although 50% to 90% of patients who receive epidermal growth factor receptor (EGFR) inhibitors develop a rash, options for rash prevention or palliation remain limited. This issue is particularly important from a palliative care standpoint because these agents are prescribed only to patients with incurable cancer. Here, we report (1) gene expression profiling of skin biopsies from patients with an EGFR inhibitor–induced rash and (2) a randomized, placebo-controlled feasibility trial with the antiandrogen, spironolactone. Both investigations were undertaken to begin to explore the hypothesis that androgens mediate EGFR inhibitor–induced rash and that antiandrogens palliate it. Methods/Results: First, 4 skin biopsies from patients with EGFR inhibitor–induced rash (3 men and 1 woman) were subject to gene expression microarray profiling. A public data set of normal skin gene expression (Gene Expression Omnibus, GSE22998) served as a reference. Sixty percent of commonly interrogated androgen receptor genes (207 of 308 between the 2 data sets) were differentially expressed ( P < .05) in the rash samples. Second, in a 17-patient double-blinded, placebo-controlled trial with topical spironolactone applied to the face, although the primary feasibility end point was not achieved, patients in the spironolactone arm received more doses of EGFR inhibitor, and anecdotal photographic evidence suggested salutatory effects of spironolactone on rash. Conclusions: Epidermal growth factor receptor inhibitor–induced rash appears to be androgen-mediated; antiandrogen therapy merits further study for rash prevention/palliation.